Malaria Parasites Use Host Cells to Evade Drugs

A recent study from the Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB) has identified a novel mechanism by which malaria parasites resist artemisinin, the most common anti-malarial drug globally. The research indicates that parasites can exploit young red blood cells, known as reticulocytes, to shield themselves from drug-induced stress.

This breakthrough study, published in The Journal of Infectious Diseases, suggests that the condition of the host cell plays a crucial role in treatment success. It challenges the established view that resistance is primarily driven by genetic mutations within the parasite itself. The findings could explain persistent infections or delayed parasite clearance in patients treated with standard drugs, even in the absence of known resistance markers.

Researchers believe these insights may pave the way for new therapeutic strategies. Future treatments could aim to disrupt the cellular environment that enables parasite survival, thereby enhancing the efficacy of existing anti-malarial medications. This approach could be particularly beneficial for children, anaemic individuals, and those with increased reticulocyte counts due to blood loss or infection.

The collaborative effort involved institutions such as BRIC-RGCB, IISER Thiruvananthapuram, Cosmopolitan Hospital, and CSIR-National Chemical Laboratory. This discovery offers a new perspective on malaria treatment, aiming to improve outcomes for millions affected worldwide by understanding complex host-parasite interactions.